Logo - springer
Slogan - springer

Biomedical Sciences - Pharmacology & Toxicology | Drug Delivery and Translational Research (Press)

Drug Delivery and Translational Research

Drug Delivery and Translational Research

An Official Journal of the Controlled Release Society

Editor-in-Chief: Vinod Labhasetwar

ISSN: 2190-393X (print version)
ISSN: 2190-3948 (electronic version)

Journal no. 13346

New York / Heidelberg, 12 July 2010

Springer launches Drug Delivery and Translational Research

New journal to focus on translational aspects of drug delivery

13346
Starting in February 2011, Springer will publish a new international, peer-reviewed journal Drug Delivery and Translational Research. Focusing exclusively on translational aspects of drug delivery, the bi-monthly journal will provide a unique forum for publication of high-quality research. It is an official journal of the Controlled Release Society (CRS).
Drug Delivery and Translational Research will publish research on such topics as designing and developing novel drug delivery systems, with a focus on their application to disease conditions; preclinical and clinical data related to drug delivery systems; short-term and long-term biocompatibility of drug delivery systems; nanomedicine, and other state-of-the-art technologies. In addition to original full-length papers, reviews, and editorial commentary, the journal will include brief communications, notice of future meetings announcements pertaining to activities of the Society. Dr. Vinod Labhasetwar of the Cleveland Clinic, Ohio, USA, is editor-in-chief. He is supported by an international editorial board with renowned experts from research centers and hospitals.
Drug Delivery and Translational Research will be published on Springer’s online platform SpringerLink including Online First™, Cross Reference Linking, and Alert services. The journal will be provided to all members of the CRS as a benefit of membership.
Diane J. Burgess, President of the Controlled Release Society, said, "I am excited about this new CRS publishing initiative. With the tremendous growth in this area and incredible advances in nanomedicine that are just now starting to reach the clinics, this is precisely the right time to launch such a drug delivery and translational journal. Supported by our international network of top experts in this field, I anticipate that this new journal will hit the ground running."
Dr. William Curtis, Executive Vice President for Publishing at Springer, said, “Springer is delighted to be partnering with the Controlled Release Society to launch this exciting new publication. Our SpringerLink online platform will provide worldwide access to its high-value content. In doing so, the Society’s publication will reach an ever growing multidisciplinary audience whose work focuses on enhancing drug delivery and optimizing the bioavailability of drug products for key disease states.”
The Controlled Release Society is an international, multidisciplinary society dedicated to the science and technology of delivering bioactives. Incorporated in 1978, the CRS is a not-for-profit organization. The international organization serves 3,000 members from more than 50 countries. Two-thirds of the CRS membership represents industry and one-third represents academia and government.
Springer is a leading global scientific publisher of books and journals, delivering quality content through innovative information products and services. It publishes close to 500 academic and professional society journals. Springer is part of the publishing group Springer Science+Business Media. In the science, technology and medicine (STM) sector, the group publishes around 2,000 journals and more than 6,500 new books a year, as well as the largest STM eBook Collection worldwide. Springer has operations in about 20 countries in Europe, the USA, and Asia, and more than 5,000 employees.
ISSN: 2190-393X (print version), ISSN: 2190-3948 (electronic version)

More about Drug Delivery and Translational Research: 

More about the Controlled Release Society: 

Contact: 

 

Articles

For authors and editors

  • Aims and Scope

    Aims and Scope

    Close

    The journal provides a unique forum for scientific publication of high-quality research that is exclusively focused on translational aspects of drug delivery. Rationally developed, effective delivery systems can potentially affect clinical outcome in different disease conditions.

    Research focused on the following areas of translational drug delivery research will be considered for publication in the journal.

      • Designing and developing novel drug delivery systems, with a focus on their application to disease conditions;
      • Preclinical and clinical data related to drug delivery systems;
      • Drug distribution, pharmacokinetics, clearance, with drug delivery systems as compared to traditional dosing to demonstrate beneficial outcomes
      • Short-term and long-term biocompatibility of drug delivery systems, host response;
      • Biomaterials with growth factors for stem-cell differentiation in regenerative medicine and tissue engineering;
      • Image-guided drug therapy,
      • Nanomedicine;
      • Devices for drug delivery and drug/device combination products.

    In addition to original full-length papers, communications, and reviews, the journal includes editorials, reports of future meetings, research highlights, and announcements pertaining to the activities of the Controlled Release Society.

  • Open Choice - Your Way to Open Access
  • Submit Online
  • Instructions for Authors

    Instructions for Authors

    Close

  • Compliance with Ethical Requirements

Alerts for this journal

 

Get the table of contents of every new issue published in Drug Delivery and Translational Research.